Lantheus to Present New Data at the ASNC Annual Scientific Session on the Novel PET Cardiac Imaging Agent Flurpiridaz F 18 in Patients with Suspected Heart Disease Undergoing Exercise Stress Testing

Findings Show Superiority of Flurpiridaz F 18 PET MPI Compared to SPECT MPI for the Assessment of Coronary Artery Disease During Exercise Stress Testing

Share This